Invest in the Future of Women’s Health
J3 Bio is advancing a patented intravaginal ring platform engineered for consistent, controlled release of active and functional ingredients. With FDA clearance for our first product (VR101), we are building a diversified portfolio designed to support women across multiple health needs and life stages.
Our platform approach allows for efficient expansion into new indications, rapid product development, and strong commercial differentiation—positioning J3 Bio at the forefront of innovation in women’s health.
Why J3
Compelling market opportunity: A rapidly growing women’s health market with strong demand for effective, easy-to-use solutions
Significant unmet need: Millions of women lack long-lasting, practical options that fit their lives
Proven technology: FDA-cleared, weekly-use LIV-Ring platform
Strong IP foundation: 4 U.S. patents and 11 international patents
Flexible platform: Designed to support multiple functional and active ingredient categories
Experienced leadership: Decades of success across med-tech, pharma, and women’s health
World-class partnerships: Collaborations with leading academic, clinical, and commercial organizations
The women’s health landscape is undergoing a major transformation, with the direct-to-consumer (DTC) market representing a ~$40B opportunity and expanding at >6% CAGR. This growth is propelled by a fundamental shift in how women seek care and make health decisions.
Women drive 80% of all healthcare spending, yet many feel underserved by traditional medical channels. As confidence in physician-led and prescription-based pathways declines, women are increasingly turning to DTC solutions that are clinically validated, accessible and effective alternatives to prescription interventions.
Market Need & Opportunity
This shift is amplified online. An estimated 30–50 million U.S. women actively shop for health and wellness products through digital channels, making DTC a primary mode of discovery and purchase of women’s health and wellness products. Meanwhile, AI is emerging as a first-line search and decision tool, accelerating the move toward digital-first brands that deliver personalized support outside of the traditional healthcare system.
Together, these forces are redefining women’s health, driving rapid adoption of DTC solutions that meet women where they are and empower them to take control of their own care.
The LIVRing platform is uniquely positioned. It harnesses these modern trends—DTC access, digital engagement, and AI-driven guidance—while operating within strict regulatory and clinical standards to ensure safety and credibility. This unique approach to product development delivers accessibility without the traditional barriers of medical visits, pharmaceutical gatekeeping, or insurance reimbursement, enabling women to access high-quality, clinically grounded solutions on their own terms.
LIVRing bridges the gap between consumer convenience and clinical rigor—meeting women where they are, while raising the bar for trust, transparency, and evidence-based care in the DTC women’s health market.